Stevanato Group S.p.A. STVN
Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Ask Irving AI About STVN
Get to know the stock you’re researching through a simple conversation. Ask Irving about its Weiss rating, financial health, dividends, and potential risks — right from the stock page.
Get answers about this stock. Instantly.
Ask about the company’s financial health and its Weiss Safety, Reward, and Risk Ratings, with answers grounded in Weiss Ratings data.
Understand the numbers behind the rating.
Explore profits, cash flow, valuation, and dividends. Ask follow-up questions without leaving the stock page.
Put the stock’s strengths and risks in context.
Look beyond a single number. Explore rating changes and company trends to better understand the stock’s outlook.
Company Overview
Stevanato Group S.p.A. is an Italian-headquartered provider of drug containment, drug delivery, and diagnostic solutions serving the global pharmaceutical, biotechnology, and life sciences industries. The company operates primarily in the healthcare manufacturing sector, with a focus on high-value glass containers, integrated systems for injectable drugs, and engineering solutions used in pharmaceutical production. Its core products include glass vials, syringes, cartridges, and specialized containment systems designed for biologics, vaccines, and other sensitive therapeutics. Revenue is largely driven by pharmaceutical customers requiring high-quality sterile containment and manufacturing support for injectable medicines.
The company traces its origins to 1949, when it was founded in Piombino Dese, Italy, by Giovanni Stevanato as a glass-forming business. Over time, it expanded from glass conversion into precision drug containment systems and pharmaceutical engineering services. Stevanato Group subsequently broadened its capabilities through investments in automation, proprietary manufacturing technologies, and integrated production systems. The company has positioned itself as a specialized supplier to large pharmaceutical and biotechnology companies by combining containment products with engineering and analytical services, particularly in the rapidly growing injectable drug market.
Business Operations
Stevanato Group organizes its operations primarily through two major business segments: Biopharmaceutical and Diagnostic Solutions and Engineering. The Biopharmaceutical and Diagnostic Solutions segment produces glass containers, ready-to-use sterile products, syringes, cartridges, and vials used in injectable therapies and diagnostics. This segment represents the majority of company revenue and serves pharmaceutical and biotechnology firms developing biologics, vaccines, insulin therapies, and other injectable drugs. The Engineering segment designs and manufactures production equipment, visual inspection systems, assembly machinery, and automation solutions for pharmaceutical manufacturing customers.
The company maintains manufacturing and commercial operations across Europe, North America, South America, and Asia. Its operational model combines proprietary glass-forming technologies, sterile processing capabilities, and integrated engineering systems intended to support pharmaceutical customers from drug development through commercial manufacturing. Stevanato Group also operates through subsidiaries and specialized entities supporting analytical services, engineering systems, and regional manufacturing operations. Strategic customer relationships with major pharmaceutical manufacturers are important to its business model, particularly in high-value injectable therapies and biologic drug delivery systems.
Strategic Position & Investments
Stevanato Group’s strategic direction has focused on expanding high-margin containment solutions, increasing production capacity for ready-to-use products, and supporting demand for biologics and injectable therapies. The company has invested substantially in manufacturing expansion projects in the United States, Italy, and China to support pharmaceutical customers seeking localized and resilient supply chains. Recent capital expenditures have emphasized advanced sterile manufacturing, high-precision glass processing, and scalable production systems for pre-filled syringes and cartridges.
The company has also expanded its analytical and testing capabilities to strengthen integration across pharmaceutical development and manufacturing workflows. Investments in automation, inspection technologies, and process engineering support its strategy of providing end-to-end solutions rather than standalone packaging products. Stevanato Group has participated in emerging sectors tied to biologics, mRNA therapies, wearable drug delivery systems, and high-performance injectable platforms. Its engineering capabilities and proprietary manufacturing technologies are considered important competitive differentiators in the pharmaceutical containment market.
Geographic Footprint
Stevanato Group is headquartered in Piombino Dese, Italy, and maintains a global operational footprint spanning Europe, North America, South America, and Asia. Manufacturing facilities and commercial offices are located in countries including Italy, the United States, Mexico, China, Slovakia, Denmark, and Brazil. The company’s international expansion has been driven largely by pharmaceutical customer demand for regional production capabilities and supply-chain diversification.
The company has strengthened its presence in the United States through production and engineering investments intended to support North American pharmaceutical customers. It also maintains a growing presence in China and broader Asian markets, where demand for injectable therapeutics and biologic manufacturing infrastructure has expanded. Stevanato Group’s customer base includes multinational pharmaceutical and biotechnology companies operating globally, giving the company broad exposure to regulated healthcare markets across multiple continents.
Leadership & Governance
Stevanato Group remains influenced by the Stevanato family, which has played a central role in the company’s historical development and governance structure. Leadership has emphasized long-term investment in pharmaceutical technologies, manufacturing quality, and innovation-driven expansion. The company operates under a governance framework consistent with publicly listed multinational healthcare suppliers and is listed on the New York Stock Exchange under the ticker STVN.
Key executives include:
- Franco Stevanato – Executive Chairman
- Marco Dal Lago – Chief Executive Officer
- Davide Stramare – Chief Financial Officer
- Aldo Ometto – Chief Technology Officer
- Stefano Capelli – Chief Commercial Officer
Management strategy has consistently emphasized operational scalability, pharmaceutical customer integration, and expansion into high-growth injectable drug markets. Public disclosures, including SEC filings, earnings materials, and investor presentations, indicate a continued focus on biologics, ready-to-use containment products, and advanced pharmaceutical manufacturing technologies.